GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinicalstage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company's common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market und ...